Original Contribution

Protective effect of arginine on oxidative stress in transgenic sickle mouse models

Trisha Dasgupta a, Robert P. Hebbel b, Dhananjay K. Kaul a,⁎

Abstract

Sickle cell disease (SCD) is characterized by reperfusion injury and chronic oxidative stress. Oxidative stress and hemolysis in SCD result in inactivation of nitric oxide (NO) and depleted arginine levels. We hypothesized that augmenting NO production by arginine supplementation will reduce oxidative stress in SCD. To this end, we measured the effect of arginine (5% in mouse chow) on NO metabolites (NOx), lipid peroxidation (LPO), and selected antioxidants in transgenic sickle mouse models. Untreated transgenic sickle (NY1DD) mice (expressing ~75% βS-globin of all β-globins; mild pathology) and knockout sickle (BERK) mice (expressing exclusively hemoglobin S; severe pathology) showed reduced NOx levels and significant increases in the liver LPO compared with C57BL mice, with BERK mice showing maximal LPO increase in accordance with the disease severity. This was accompanied by reduced activity of antioxidants (glutathione, total superoxide dismutase, catalase, and glutathione peroxidase). However, GSH levels in BERK were higher than in NY1DD mice, indicating a protective response to greater oxidative stress. Importantly, dietary arginine significantly increased NOx levels, reduced LPO, and increased antioxidants in both sickle mouse models. In contrast, nitro-L-arginine methylester, a potent nonselective NOS inhibitor, worsened the oxidative stress in NY1DD mice. Thus, the attenuating effect of arginine on oxidative stress in SCD mice suggests its potential application in the management of this disease.

© 2006 Elsevier Inc. All rights reserved.

Keywords: Sickle cell disease; Oxidative stress; Arginine; Lipid peroxidation; Antioxidants

Introduction

Increasing evidence accumulated over the last decade indicates that reactive oxygen species (ROS) play a crucial role in the pathophysiology of various ischemic diseases. The concept that sickle cell disease (SCD) is a state of inflammation has been substantiated by the reports of endothelial injury/activation and excessive generation of ROS in this disease, and enhanced leukocyte-endothelium interactions [3,13,15,31]. The oxidative stress in SCD is likely the result of intravascular sickling and transient vaso-occlusive events.

In SCD, growing evidence shows reduced bioavailability of nitric oxide (NO), probably due to consumption of NO by free oxygen radicals, and/or by cell-free plasma heme as a result of hemolysis [3,35]. In SCD and sickle mouse models, a preponderance of recent observations shows depleted levels of L-arginine, a substrate for NO, and NO metabolites (NOx) [24,25,36]. However, there is no definitive data on the status of antioxidant enzyme and lipid peroxidation according to the disease severity, as well as on the effect of NO replenishment. Among the likely sources of O2·− in SCD are plasma membrane NADPH oxidase [12,44], enzyme NO synthase due to depleted substrate arginine [40], and increased plasma xanthine oxidase (XO) activity [3,41].

NO has important salutary physiological properties like vascular tone regulation, quenching reactive oxygen intermediates, and inhibiting leukocyte recruitment in the microcirculation [2,15,17,22,27,29]. Depleted NO production in a transgenic-knockout (BERK) model is associated with increased tyrosine nitration [16], suggesting that hemolysis in this
model may trigger the reported hemin-mediated nitrotyrosine formation in the presence of nitrite and hydrogen peroxide (\(\text{H}_2\text{O}_2\)) [38]. L-Arginine (a substrate for NO) and several NO donors can decrease the damage resulting from postischemic reperfusion [14]. Arginine blunts the inhibitory effect of XO on vascular function [42]. In renal ischemic-reperfusion injury, NO can protect the kidneys against leukocyte adhesion to vascular endothelium [29]. In contrast, inhibition of NO production by (nitro-L-arginine methylester) L-NAME, a potent nonselective inhibitor of nitric oxide synthase (NOS), causes in an inflammatory response, resulting in increased leukocyte-endothelium interaction [17] and oxidant generation [18].

Although the increased leukocyte counts in human SCD and transgenic sickle mouse models suggest a systemic effect of oxidative stress, a direct evidence of organ oxidative stress requires biochemical estimations of oxidative stress and cellular antioxidants. Among the many consequences of ischemia/reperfusion injury are increased oxidant generation, peroxidation of the membrane lipids, and reduced antioxidants, both nonenzymatic (e.g., glutathione [GSH]) and enzymatic antioxidants (e.g., superoxide dismutase [SOD], catalase, and glutathione peroxidase [GPx]) [28]. Lipid peroxidation is perhaps the most recognized biological effect of oxygen radicals that occurs when free radicals react directly with cellular lipids. Lipid peroxidation results in damage to the cell membrane, as well as to the membrane of cellular organelles (e.g., mitochondria). Among the best characterized enzymatic pathways are SOD, catalase, and GPx. SOD dismutates toxic \(\text{O}_2^\cdot\) into less toxic \(\text{H}_2\text{O}_2\). Because \(\text{H}_2\text{O}_2\) is a potential source for hydroxyl (OH) radical, two additional enzymatic antioxidants (catalase and GPx) transform it to water. GPx is specific for GSH (a nonenzymatic antioxidant) as a hydrogen donor, but accepts peroxides as well as \(\text{H}_2\text{O}_2\). During reperfusion, these endogenous defenses are likely to be ineffective as a result of overproduction of oxygen radicals. Additionally, during ischemia/reperfusion, degradation/consumption of antioxidants by the release of oxygen radicals has been well-documented [28]. Thus, failure to replenish antioxidants is expected to exacerbate the reperfusion injury and organ damage in SCD.

We hypothesize that in SCD, increased oxidative stress will result in increased lipid peroxidation and a decreased activity of antioxidants. To test this aspect, we have used transgenic mouse models of mild (NY1DD mice) and severe pathology (BERK mice). Transgenic NY1DD mice show a mild phenotype but develop an inflammatory phenotype after hypoxia/reoxygenation as evident by increased lipid peroxidation and leukocyte recruitment [15,31]. Transgenic-knockout BERK mice express exclusively human hemoglobin S, and recapitulate many features of human sickle cell disease, i.e., hemolytic anemia, reticulocytosis, presence of irreversibly sickled cells (ISCs), and multiple organ damage [33,37]. In the current studies, we have investigated the level of oxidative stress in unperturbed (untreated) sickle mouse models and after arginine supplementation and L-NAME treatment. Our result show distinct effect of disease severity in these sickle mouse models on oxidative stress, and a protective effect of arginine supplementation.

### Materials and methods

#### Chemicals

Butylated hydroxytoluene (BHT), desferrioxamine (Desferal), 5,5-dithiobis-2-nitrobenzoic acid (DTNB), glutathione (GSH), oxidized glutathione (GSSG), pyrogallol, Triton X-100, ethylenediaminetetraacetic acid (EDTA), bovine serum albumin (BSA), thiobarbituric acid (TBA), reduced nicotinamide adenine dinucleotide (NADH), and reduced nicotinamide adenine dinucleotide phosphate (NADPH) were obtained from Sigma/Aldrich (St. Louis, MO).

#### Transgenic mice

Transgenic (NY1DD) and knockout (BERK) mice, used in the present studies, were raised in a specific pathogen-free facility at the University of Minnesota Medical School. NY1DD mice were backcrossed an average of 8 generation into C57BL/6J background. In NY1DD mice, \(\beta^\text{s}\)-globin forms symmetrical tetramers with human \(\alpha\)-globin (42%) and with mouse \(\alpha\)-globin (∼30%). In these mice, the total \(\beta^\text{s}\)-globin levels are ∼75% of all \(\beta\)-globins [8]. NY1DD mice show mild pathology, but exhibit multiple organ damage [7]. NY1DD mice show no hemolysis and systemic hematocrit (%) in NY1DD mice is similar to that found for C57BL control mice (mean ± SD: NY1DD mice, 47.5 ± 3; controls, 46.5 ± 2.1) [7]. Transgenic-knockout BERK mice express 100% human \(\alpha\) and >99% human \(\beta^\text{s}\), and show severe pathology. BERK mice exhibit several features of human SCD, i.e., hemolysis, reticulocytosis, low hematocrit, and extensive multiple organ damage [33,37]. Hemolytic anemia in BERK mice is associated with significantly low systemic hematocrit, i.e., 28.7 ± 4.0 (\(p < 0.00001\) vs controls) [16]. Globin composition was determined by denaturing HPLC as described [9].

#### L-Arginine supplementation

Mice of each genotypes (C57BL/6J, NY1DD and BERK mice, \(n = 4-6\); 4-6 months of age) received dietary 5% arginine supplementation in mouse chow (Harlan-Teklad, Madison, WI) for a period of 15 days. In each case, controls (untreated) were maintained on normal mouse chow without added arginine.

#### L-NAME treatment

Control C57BL mice (\(n = 9\)) and NY1DD mice (\(n = 7\)) were given 1 mg/ml L-NAME (Sigma/Aldrich) in drinking water for 7 days. Controls were given plain drinking water ad libitum.

#### NO metabolite (NOx) determination

For the determination of NO metabolites, NOx, the blood was drawn from bifurcating abdominal aorta using EDTA as an anticoagulant. Total NOx concentration in plasma was determined using a nitrate/nitrite colorimetric assay kit (Cayman Chemical, Ann Arbor, MI) using the manufacturer’s instructions.
In brief, the method involves a two-step process. The first step involves conversion of nitrate to nitrite utilizing nitrate reductase. The second step consists of adding Greiss reagents that convert nitrite into deep purple azo compound. The photometric determination of the absorbance at 540 nm of this azo compound accurately determines nitrite concentration.

**Preparation of homogenates, cytosol, and microsome fractions**

Mice were sacrificed by cervical dislocation and the entire liver was then perfused immediately with cold 0.9% NaCl and thereafter carefully removed, trimmed free of extraneous tissue, and rinsed in chilled 0.15 M Tris-KCl buffer (0.15 M KCl + 10 mM Tris-HCl, pH 7.4). The liver was then blotted dry, weighed quickly, and homogenized in ice-cold 0.15 M Tris-KCl buffer (pH 7.4) to yield 10% (w/v) homogenate. An aliquot of this homogenate (0.5 ml) was used for assaying reduced glutathione and for assaying lipid peroxidation. The kidney and the muscle from the hind legs were carefully removed, along with the liver, trimmed free of extraneous tissue, and rinsed in chilled 0.15 M Tris-KCl buffer (0.15 M KCl + 10 mM Tris-HCl, pH 7.4). The supernatant (cytosol fraction), after discarding any floating lipid layer and appropriate dilution, was used for the assay of antioxidant enzymes, whereas the pellet representing microsomes was suspended in homogenizing buffer and used for assaying lipid peroxidation. The kidneys and the muscle from the legs were carefully removed, along with the liver, trimmed free of extraneous tissue, and rinsed in chilled 0.15 M Tris-KCl (pH 7.4). The organs were then blotted dry, weighed quickly, and homogenized in ice-cold 0.15 M Tris-KCl buffer (pH 7.4) to yield a 10% (w/v) homogenate. A 0.5-ml aliquot of this homogenate was used for assaying reduced glutathione. The rest of the homogenate was processed as described for the liver.

**Assay methods**

**Lipid peroxidation (LPO)**

LPO in the microsomes was estimated spectrophotometrically by thiobarbituric acid reactive substances (TBARS) method, as described by Ohkawa et al. [30] and is expressed in terms of malondialdehyde (MDA) formed per milligram protein. To validate our TBARS results, in a series of experiments, we measured LPO (i) using an iron chelator and an antioxidant in the microsomal preparation and (ii) using an enzyme immunoassay (EIA) for the determination of 8-isoprostanes.

In the first approach (TBARS), liver and/or muscle microsomal fraction was suspended in Tris-KCl, so as to contain approximately 1 mg protein in 0.1 ml suspension. An aliquote of 0.25 ml was mixed with 1.75 ml LPO buffer containing 50 μM desferrioxamine (desferal) and 0.1 ml of 2% butylated hydroxytoluene in ethanol. Thereafter, 0.5 ml of 30% trichloroacetic acid (TCA) and 0.5 ml of 52 mM thiobarbituric acid was added to the mixture. Desferal was added to prevent further iron-catalyzed TBARS formation [5] and BHT was used to prevent further lipid peroxidation [10]. The reaction mixture was processed for the measurement of TBARS as described [30].

In the second approach, we measured total (free and esterified) 8-isoprostanes in the liver using an EIA kit (Cayman Chemicals, Ann Arbor, MI). The liver tissue were weighed and homogenized in 3 vol of 0.1 M phosphate buffer, pH 7.4, containing 1 mM EDTA and 10 μM indomethacin under cold conditions (1 g tissue in 3 ml phosphate buffer). The homogenate was centrifuged at 1680 g at 4°C for 10 min. Further, alkaline hydrolysis was performed adding an equal volume of 15% w/v KOH and was incubated for 60 min at 40°C. Thereafter, 2 vol of ethanol containing 0.01% BHT was added to the sample and incubated for 5 min at 4°C. This was followed by centrifugation at 1500 g for 10 min to remove precipitated proteins. The supernatant was decanted into a clean test tube and ethanol was evaporated (to <10% v/v) under a gentle stream of nitrogen. Samples were finally rediluted in 500 μl of 0.1 M phosphate buffer (pH 7.4). The assay employs an Ellman’s reaction producing an absorbance at 412 nm proportional to the amount of 8-isoprostane tracer bound to the well and it is inversely proportional to 8-isoprostane in the well. To test for interference, initially few test samples (n = 7) were diluted to obtain two different dilutions of each sample between ~5 and 200 pg/ml. Two different dilutions of the samples showed good correlation (i.e., differed by less than 8%). Since the difference was less than 20%, purification was not needed according to the manufacturer’s instructions.

**Glutathione (GSH)**

GSH was estimated as total nonprotein sulfydryl group by the method as described by Moron et al. [23].

**Superoxide dismutase**

Total SOD was assayed utilizing the technique of Marklund and Marklund [21], which involves inhibition of pyrogallol autoxidation at pH 8.0. A single unit of enzyme was defined as the quantity of superoxide dismutase required to produce 50% inhibition of autoxidation.

**Catalase**

Catalase was estimated at 240 nm by monitoring the disappearance of H₂O₂ as described by Aebi [1]. The reaction mixture (1 ml, vol) contained 0.02 ml of suitably diluted cytosol in phosphate buffer (50 mM, pH 7.0) and 0.1 ml of 30 mM H₂O₂ in phosphate buffer. Catalase enzyme activity has been expressed as moles of H₂O₂ reduced per minute per milligram protein.

**Glutathione peroxidase**

GPx activity was measured by the coupled assay method as described by Paglia and Valentine [32]. One unit of enzyme activity has been defined as nanomoles of NADPH consumed per minute per milligram protein based on an extinction coefficient of 6.22 mM⁻¹ cm⁻¹.

**Statistical analysis**

Statistical analysis of the data (mean ± SD) was performed using Student’s t test. p < 0.05 was considered significant. The
statistical analysis was performed using Statgraphics plus 5.0 program for Windows (Manugistics, Inc. Rockville, MD). Iso-
prostane calculation was performed using the analysis spreadsheet provided by Cayman Chemical at http://www.caymanchem. com/app/template/Home.vm.

Results

Effect of arginine supplementation

Plasma NOx levels

As shown in Fig. 1, NOx levels in untreated NY1DD and BERK mice were 51.7 and 78.7% lower, respectively, than control C57BL values ($p < 0.000001$ each), indicating the minimal NO production in more severe BERK mice. While arginine caused $\sim 20\%$ increase in NOx concentration in control C57BL mice ($p < 0.0004$), it resulted in marked 86.2 and 107% increases in NOx levels, respectively, in NY1DD and BERK mice ($p < 0.0001$ and $p < 0.001$) compared with untreated mice, indicating that arginine caused significant increases in NO production in both transgenic sickle mice.

Lipid peroxidation

Fig. 2A depicts the results of LPO estimations in the liver of C57BL, NY1DD, and BERK mice in the presence of desferal plus BHT. LPO values showed marked 67 and 150% increases, respectively, in untreated NY1DD and BERK mice as compared to C57BL controls (each $p < 0.001$). Arginine supplementation (15 days in mouse chow) had no effect on LPO levels in C57BL mice. On the other hand, LPO levels decreased 11% in NY1DD mice ($p < 0.05$ vs untreated NY1DD), while maximal decrease (49%) was observed in BERK mice ($p < 0.0001$ vs untreated BERK).

Measurement of total 8-isoprostanes (in the presence of BHT) in the liver validated the marked differences among untreated groups (Fig. 2B). Isoprostanes showed 91 and 326% increases in NY1DD and BERK mice as compared with C57BL mice (each $p < 0.001$), confirming the trend observed with the TBARS method. Again, 8-isoprostane levels in these mice were directly proportional to the disease severity. In contrast to the above TBAR results, arginine had a pronounced ame-
liorating effect on isoprostane levels. While arginine had no effect in controls as also shown by TBARS method, it caused 43 and 37.7% decreases in isoprostane levels in NY1DD and BERK mice as compared with corresponding untreated groups ($p < 0.001$ and $p < 0.005$, respectively).

Antioxidants

Glutathione

As shown in Fig. 3, GSH levels in various tissues were significantly reduced in both NY1DD and BERK mice as compared with C57BL controls ($p < 0.05-0.001$). Importantly, in both sickle mouse models, arginine supplementation caused recovery of GSH levels almost to the control baseline values. Interestingly, among untreated mice, GSH levels in untreated BERK mice were $\sim 23-27\%$ lower in any given tissue than those in the control C57BL mice ($p < 0.05-0.01$), but were $\sim 35-39\%$ higher as compared with less severe NY1DD mice ($p < 0.01$). The possible significance of this finding is discussed later.

Superoxide dismutase

As shown in Fig. 4, both NY1DD and BERK mice showed significant decreases ($\sim 34$ to $60\%$) in total SOD activity in the
organs examined ($p < 0.02-0.001$ vs C57BL). In arginine-treated C57BL mice, SOD activity showed somewhat variable tissue responses: no change was noted in the muscle; a $\sim 36\%$ decrease in kidney ($p < 0.001$); and a $38\%$ increase in the liver ($p < 0.001$). In contrast, arginine significantly augmented SOD activity in both NY1DD and BERK (Fig. 4) as compared to the respective untreated controls (muscle, $p < 0.05$ and $p < 0.001$, respectively; kidney, each $p < 0.01$; liver, $p < 0.01$ and $p < 0.001$), with BERK mice showing a greater recovery in the muscle and kidney SOD activity (not different from C57BL baseline values).

Catalase

Untreated NY1DD and BERK mice showed marked decreases in catalase activity (Fig. 5). The muscle catalase showed maximal decreases ($57.4\%$ in NY1DD and $\sim 50\%$ in BERK mice, each $p < 0.001$ vs C57BL), while the kidney and liver of both transgenic models showed $\sim 36$ to $43\%$ decreases ($p < 0.02-0.01$ vs C57BL). In C57BL mice, arginine resulted in no significant changes in catalase activity except a $23\%$ increase in the kidney ($p < 0.01$). In contrast, NY1DD mice treated with arginine showed $\sim 98$ and $25\%$ increases in catalase activity in the muscle and liver tissues as compared with the untreated NY1DD mice; the resulting activity was not significantly different from the baseline values in untreated C57BL mice. In BERK mice arginine caused marked $52$-$86\%$ increases in catalase activity in all the tissues ($p < 0.003-0.001$ vs untreated BERK) and the values in the kidney and liver were not significantly different from the C57BL values.

Fig. 3. Glutathione (GSH) in C57BL, NY1DD, and BERK mice: the effect of arginine supplementation. *$p < 0.05$-$<0.001$ vs C57BL controls; $\#p < 0.01$-$0.001$ vs untreated NY1DD mice; $+p < 0.01$-$0.001$ vs untreated BERK mice.

Fig. 4. Superoxide dismutase (SOD) activity in C57BL, NY1DD, and BERK mice: the effect of arginine supplementation. *$p < 0.02-0.001$ vs C57BL controls, $\#p < 0.05$-$0.001$ vs untreated NY1DD mice, $+p < 0.01$-$0.001$ vs untreated BERK mouse.
Glutathione peroxidase

In the tissues examined, GPx activity showed significant 38 to 45% decreases in NY1DD ($p < 0.01$-$0.001$) and even more marked 56 to 69% decreases in BERK mice ($p < 0.02$-$0.001$) as compared with C57BL controls (Fig. 6). Thus, GPx activity was directly proportionate to the severity of SCD mice. In C57BL mice, arginine supplementation had no significant effect on GPx activity in the muscle and kidney, but resulted in a significance increase in the liver ($p < 0.001$). In contrast, arginine supplementation in NY1DD mice increased GPx activity in all the tissues by 29 to 48% ($p < 0.03$-$0.01$ vs untreated NY1DD), and resulted even in more marked increase in the BERK tissues, i.e., $\sim 1.5$- to $\sim 3.0$-fold increases ($p < 0.02$-$0.001$ vs untreated BERK) (Fig. 6). GPx activity in the kidney and liver of arginine-treated BERK mice was not significantly different from the C57BL values.

**Effect of L-NAME**

We investigated the effect of L-NAME, a potent nonselective inhibitor of NO synthase, (1 mg/ml in drinking water for 7 days) in control C57BL and transgenic NY1DD mice. The objective of these experiments was to ascertain if NO depletion in NY1DD mice with mild pathology would induce an inflammatory phenotype.

**Lipid peroxidation**

The TBARS (with desferal and BHT) method was performed in both muscle and liver tissue whereas 8-isoprostane was estimated in the liver. As shown in Table 1, L-NAME
pretreatment (1 mg/ml in drinking water for 1 week) resulted in marked 4- and 2.2-fold increases in the muscle LPO levels (TBARS) in C57BL and NY1DD mice as compared with respective controls (each p < 0.01). Also, L-NAME treatment resulted ~2.0- and 2.2-fold increases in the liver of C57BL and NY1DD mice (p < 0.01 vs respective controls).

Similarly, 8-isoprostanes showed significant increases in the liver tissue with L-NAME treatment in C57BL and NY1DD mice. L-NAME resulted in 2.2- and 1.3-fold increases in 8-isoprostanes in C57BL and NY1DD mice, respectively (p < 0.01 vs respective controls). Notably, in untreated BERK mice, liver isoprostane levels were ~1.7-fold higher (p < 0.002) than L-NAME-treated NY1DD mice (see Fig. 2B), suggesting that chronic depletion of NO substrate arginine [37] in BERK mice resulted in a greater lipid peroxidation.

**Antioxidants**

**Glutathione**

In control C57BL mice, L-NAME pretreatment caused only a slightly insignificant decrease in GSH in any given tissue (Table 1). In contrast, untreated mice NY1DD mice showed a distinct 24 to 39% reduction in GSH in these tissues after L-NAME treatment (p < 0.01-0.001).

**Superoxide dismutase**

In C57BL mice, L-NAME treatment resulted in a marked 30 to 62% reduction in SOD activity in the tissues (p < 0.001-0.001 vs untreated C57BL) (Table 1). In contrast, L-NAME treatment in NY1DD mice caused further decrease in SOD activity in all the tissues (19.3 to 30.2%, p < 0.027-0.001 vs untreated NY1DD).

**Catalase**

Catalase activity in untreated NY1DD mice was decreased 35.6 to 57.4% in all the tissues as compared with C57BL mice (p < 0.01) (Table 1). In NY1DD mice, L-NAME treatment caused a further decrease in catalase activity in the organs examined (p < 0.05-0.001 vs untreated NY1DD).

**Glutathione peroxidase**

L-NAME treatment caused significant reduction in GPx activity in both C57BL and NY1DD mice in all the investigated organs (p < 0.001 vs respective untreated controls), with NY1DD mice showing minimal values (Table 1).

**Discussion**

The primary event of the SCD is polymerization of deoxygenated sickle hemoglobin that can disrupt blood flow to the affected tissue. Oxidative damage resulting from transient occlusive events can be attributed to oxygen free radicals after restitution of blood flow, ("reperfusion injury") [13,31,43]. The present studies show that the extent of oxidative stress (e.g., lipid peroxidation level and activity of certain endogenous antioxidants) in sickle mouse models is reflective of the disease severity. The disease severity in the context of this study refers to the sickling ability of red cells in NY1DD (mild pathology) and BERK mice (severe pathology) which is proportional to the percentage of \( \beta^S \)-globin synthesis in these models (see Materials and methods). BERK mice, expressing exclusively human \( \alpha \)- and \( \beta^S \)-globins, show maximal intravascular sickling, hence frequent transient vaso-occlusive events [16,33,39]. Importantly, we show that the replenishment of NO by dietary

### Table 1

<table>
<thead>
<tr>
<th>Tissue</th>
<th>C57BL mice</th>
<th>NY1DD mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOD (μmol/mg protein)</td>
<td>n = 6</td>
<td>n = 6</td>
</tr>
<tr>
<td>Muscle</td>
<td>13.7 ± 1.4</td>
<td>12.8 ± 1.0</td>
</tr>
<tr>
<td>Liver</td>
<td>18.5 ± 2.4</td>
<td>11.6 ± 0.3</td>
</tr>
<tr>
<td>Catalase (μmol H₂O₂/min/ mg protein)</td>
<td>n = 6</td>
<td>n = 4</td>
</tr>
<tr>
<td>Muscle</td>
<td>54.5 ± 7.1</td>
<td>27.1 ± 5.3</td>
</tr>
<tr>
<td>Kidney</td>
<td>197.7 ± 19.7</td>
<td>118.8 ± 5.8</td>
</tr>
<tr>
<td>Liver</td>
<td>231.2 ± 41.3</td>
<td>124.9 ± 17.6</td>
</tr>
<tr>
<td>GPx (μmol NADPH/min/ mg protein)</td>
<td>n = 6</td>
<td>n = 4</td>
</tr>
<tr>
<td>Muscle</td>
<td>61.9 ± 5.0</td>
<td>28.4 ± 2.7</td>
</tr>
<tr>
<td>Kidney</td>
<td>39.2 ± 6.8</td>
<td>21.5 ± 1.1</td>
</tr>
<tr>
<td>Liver</td>
<td>33.7 ± 3.4</td>
<td>17 ± 1.5</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD.

* \( p < 0.01 \) vs untreated C57BL mice.

** \( p < 0.001 \) vs untreated NY1DD mice.
arginine results in significant decrease in oxidative stress in these transgenic sickle models.

Effect of disease severity

The results show that decreased NO bioavailability, as indicated by reduced NO metabolites (NOx) levels, is proportional to the disease severity in sickle mouse models, with BERK mice showing minimal NOx levels. The reduced NOx levels in sickle mice are in agreement with findings in human sickle cell patients and are associated with arginine deficiency [24,25].

Furthermore, depleted NO metabolites in transgenic (NY1DD) and knockout (BERK) sickle mice are associated with increased oxidative stress. We show that LPO, a marker of peroxidation of membrane lipids by peroxides, is significantly increased in both transgenic NY1DD mice and knockout BERK mice as compared with C57BL mice. Notably, BERK mice showed higher LPO levels compared with NY1DD mice (see Fig. 2). This pattern was confirmed whether using the TBARS method in the presence of desferal and BHT (Fig. 2A), or using 8-isoprostane determination in the liver tissue (see Fig. 2B). In BERK mice as in human SCD, chronic depletion of arginine levels, reduced NO production, and NO consumption by the plasma heme as reported before [11,24,26,35] may all contribute to a proinflammatory milieu and in greater LPO levels.

Distinct increases in LPO among NY1DD and BERK mice were accompanied by marked decreases in antioxidant enzymes (i.e., total SOD, catalase and GPx) in the tissues compared with control C57BL values. The decreases in antioxidant enzymes in sickle mouse models suggest consumption/inactivation of antioxidant enzymes by excessive reactive oxygen species in these models. This is in conformity with the observations that ischemia-reperfusion injury and increased oxidative stress (e.g., superoxide [O$_2^-$]) and hemolysis (e.g., BERK model) lead to consumption and depletion of endogenous NO and antioxidants [26].

Nonenzymatic GSH also showed significant decreases in the same tissues in both untreated NY1DD and BERK mice, but the decrease was not proportionate with the β-globin level and the disease severity of these mice. For example, the GSH level was higher in BERK mice as compared with NY1DD mice ($p < 0.05-0.001$) (see Fig. 4). GSH is initially depleted by ischemia/reperfusion and by inflammatory cytokines (e.g., TNF-α) but shows a rebound as an adaptive response to oxidative stress [28,34]. The higher GSH activity in BERK mice as compared with less severe NY1DD mice may be a protective response to a greater oxidative stress in this model caused by recurring ischemic-reperfusion events, increased levels of inflammatory cytokines, and higher levels of protein nitration [16] that are known to enhance GSH synthesis [34]. GSH effectively scavenges reactive oxygen species directly and indirectly via enzymatic reactions [45]. Furthermore, GPx catalyzes GSH-dependent reduction of H$_2$O$_2$ and other peroxides [20]. Induction of mitochondrial peroxynitrite by sodium nitroprusside, an NO donor, can also induce GSH synthesis [19]. In fact, BERK mice show several-fold increase in nitrotyrosine [16], probably because initial higher production of NO in this model and in human SCD is followed by consumption of NO by oxygen radicals and plasma heme that could lead to increased metabolism and depletion of arginine substrate [25,35].

Protective effect of arginine

Both human SCD and sickle mouse models are characterized by reduced NO bioavailability due to enhanced consumption of NO as noted above. In BERK mice, the destruction of NO and concomitant arginine deficiency results in induction of other vasodilatory mechanisms (e.g., induction of cyclooxygenase-2 and enhanced prostacyclin production) to compensate for NO deficiency and to maintain optimal blood flow in the face of chronic hemolytic anemia in this model [16].

Arginine supplementation resulted in significant increases in plasma NOx levels in C57BL control, NY1DD, and BERK mice. In contrast to C57BL mice wherein arginine resulted in a smaller increase in NOx levels (perhaps due to already higher NOx levels), both NY1DD and BERK mice showed marked increases in NOx levels over the untreated control groups. Although arginine treatment in NY1DD mice raised the NOx values almost to the level seen in C57BL mice, the increase in BERK mice was not sufficient to normalize the values to C57BL baseline values (see Fig. 1).

While arginine had minimal effect on the liver LPO in C57BL mice, NY1DD mice with moderate oxidative stress exhibited significant decrease in LPO (e.g., isoprostanes) levels in the liver; the resulting values were not significantly different from control C57BL baseline values. Also, arginine resulted in an overall reduction in LPO in BERK mice, though it did not normalize the values. However, the marked overall efficacy of dietary arginine on LPO reduction in BERK mice is a likely due to the replenishment of endogenous arginine levels, as noted before.

Antioxidative effect of arginine supplementation was further evident by a marked recovery of GSH in both NY1DD and BERK mice almost to the C57BL baseline levels in any given tissue. Also, following arginine supplementation, antioxidant enzymes showed a marked increase: SOD activity showed almost complete normalization in the kidney and liver of NY1DD mice and in the muscle and kidney of BERK mice, accompanied by marked increase in catalase activity in all the tissues examined except for the kidney in NY1DD mice; GPx which along with catalase scavenges H$_2$O$_2$ showed significant increases in all the tissues in both NY1DD and BERK mice.

These results strongly suggest that increased NO production after arginine treatment exerts an anti-inflammatory effect not only by reducing LPO levels but also by enhancing protective antioxidant mechanisms in both transgenic NY1DD and knockout BERK models of SCD. Although NY1DD mice do not exhibit hemolysis, BERK mice show more than 2-fold increase in cell-free plasma heme compared with controls [16] that may result in consumption/inactivation of NO by ferrous hemoglobin as described [35]. In addition, transient vaso-occlusive events in BERK mice, caused by intravascular sickling, will result in reperfusion injury and oxidant generation
contributing to NO consumption by \(O_2^-\) \[3,16\]. Thus, arginine supplementation is likely to enhance NO production and reduce oxidative stress in models of hemolysis and reperfusion injury \[4,6,24\].

**Inflammatory effect of L-NAME**

Since L-NAME competes with endogenous arginine to reduce NO production, the marked increase in oxidative stress in both C57BL and NY1DD mice following L-NAME treatment is in accord with the inflammatory effects of reduced NO availability that characterizes SCD \[16,35\]. This was evident by not only increased LPO levels but also a marked decrease in various antioxidants, i.e., GSH, SOD, catalase, and GPx (see Table 1). We did not treat BERK mice with L-NAME as our previous studies have shown that L-NAME has no effect on blood pressure or vessel (arteriolar) diameters in these mice\[16\], suggesting drastically depleted endogenous arginine levels. Using transgenic NY1DD mice, these results suggest that reduced NO bioavailability would play a major role in the inflammatory state in SCD.

In conclusion, the present studies demonstrate that reperfusion injury in transgenic (NY1DD) and knockout (BERK) mice caused by intravascular sickling and vaso-occlusive events results in increased LPO and decreased antioxidants as compared with C57BL mice. Furthermore, there is a distinct relationship between disease severity and LPO levels, with pathologically more severe BERK mice showing maximal LPO. While antioxidant enzymes showed decreases in both models, GSH decrease in BERK mice was not as pronounced as in NY1DD mice, suggesting that in severe BERK mice, recurring ischemia/reperfusion events, inflammatory cytokines, and protein nitration might induce GSH synthesis as a protective response. Importantly, arginine supplementation in both mouse models reduced oxidative stress and enhanced antioxidant activity, suggesting that increased NO bioavailability after arginine treatment (as indicated by increased NOx levels) had anti-inflammatory effects on the organ oxidative stress. In contrast, a decrease in NO bioavailability after L-NAME treatment resulted in a marked increase in oxidative stress in transgenic NY1DD mice. These results demonstrate that replenishment of NO by arginine supplementation significantly decreases oxidative stress in SCD mice, suggesting a potential therapeutic use of arginine in the management of this disease.

**Acknowledgments**

This work was supported by National Heart, Lung, and Blood Institute Grants P01 HL-55552 and RO1 HL-070047.

**References**


[23] Moron, M. S.; DePierre, J. W.; Mannervik, B. Levels of glutathione,


